Last update Jan. 17, 2022

Milrinone

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Amrinone is a phosphodiesterase type 3 inhibitor, similar to milrinone, with positive vasodilator and inotropic properties. Indicated in the treatment of heart failure. Intravenous administration (oral administration has too many side effects).

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data (low molecular weigh and low protein binding) make it likely that it would pass into breast milk in amounts which could be significant.

Milrinone and amrinone have a slower elimination rate in newborns and young infants and a higher risk of potentially serious side effects. (Sanofi 2016, Laitinen 2000, Ramamoorthy 1998)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Kearney 2018), especially during the neonatal period and in the event of prematurity.

If used during lactation: express and discard breast milk and wait to breastfeed 8 to 10 hours after administration.


See below the information of this related product:

  • Amrinone ( Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Milrinone is also known as


Milrinone in other languages or writings:

Group

Milrinone belongs to this group or family:

Tradenames

Main tradenames from several countries containing Milrinone in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 80 %
Molecular weight 211 daltons
Protein Binding 70 %
VD 0.38 - 0.45 l/Kg
pKa 7.54 -
Tmax 0.03 - 0.08 hours
2.3 hours

References

  1. Kearney L, Wright P, Fhadil S, Thomas M. Postpartum Cardiomyopathy and Considerations for Breastfeeding. Card Fail Rev. 2018 Abstract Full text (link to original source) Full text (in our servers)
  2. Sanofi-Aventis. Milrinona. Ficha técnica. 2016 Full text (in our servers)
  3. Sandoz. Milrinone. Drug Summary. 2009 Full text (in our servers)
  4. Laitinen P, Ahonen J, Olkkola KT, Peltola K, Rautiainen P, Räsänen J. Pharmacokinetics of amrinone in neonates and infants. J Cardiothorac Vasc Anesth. 2000 Aug;14(4):378-82. Abstract
  5. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet. 1998 Abstract
  6. Ramamoorthy C, Anderson GD, Williams GD, Lynn AM. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesth Analg. 1998 Feb;86(2):283-9. Abstract
  7. Edelson J, Stroshane R, Benziger DP, Cody R, Benotti J, Hood WB Jr, Chatterjee K, Luczkowec C, Krebs C, Schwartz R. Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation. 1986 Mar;73(3 Pt 2):III145-52. Abstract

Total visits

3,429

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM